VivoSeq
Other

Prevention

0

Pipeline Programs

62

Active Trials

34

Companies Involved

Prevention is an early-stage landscape with 0 programs across 34 companies. The most active players are AstraZeneca, MediQuest Therapeutics, GSK.

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

36/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

13/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

463

clinical trials

Completed259 · 56%
Unknown status83 · 18%
Terminated41 · 9%
Recruiting38 · 8%
Withdrawn17 · 4%
Not yet recruiting12 · 3%
Other13 · 3%

Trial Activity

463 trials

CaOx Stone Prevention
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT07225764·80 enrolled
Rectal NSAIDs With/Without PD Stent for PEP Prevention
Recruiting··N/A·NCT07117318·1,278 enrolled
Page 1 of 31

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)